GH Research PLC
NASDAQ: GHRS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Velichka Valcheva
- Employees
- 50
- Headquarters
- Dublin, Ireland
- IPO year
- 2021
- Market cap
- $1.7B
- Website
- https://www.ghres.com
Loading GHRS…
Loading profile data…Frequently asked questions about GHRS
What does GH Research PLC (GHRS) do?
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced progra...
Where does GHRS trade?
GH Research PLC (GHRS) trades on the NASDAQ Global Market.
What sector is GHRS in?
GH Research PLC (GHRS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GH Research PLC?
Velichka Valcheva is the chief executive officer of GH Research PLC (GHRS).
Where is GH Research PLC headquartered?
GH Research PLC is headquartered in Ireland.
Does GHRS pay a dividend?
GH Research PLC (GHRS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GHRS go public?
GH Research PLC (GHRS) completed its initial public offering in 2021.